Three highly publicised outbreaks of iatrogenic disease have affected Britain in the past 20 years. The thalidomide affair resulted in legal controls on the investigation and marketing of new pharmaceutical products; the practolol episode produced a prolonged period of introspection but no further legislative action; and the problems with benoxaprofen should herald a re-evaluation of our current approaches to postmarketing surveillance of adverse reactions.
In the past techniques such as individual case reports,' the Committee on the Safety of Medicines' "yellow card" system,2 monitoring national mortality statistics,3 and case-control studies4 have successfully identified adverse drug reactions. But the most powerful method, where feasible, remains the cohort investigation, which was used to such effect in the Royal College of General Practitioners' oral contraception study .3 In the aftermath of practolol several proposals were made independently for a cohort approach to the identification and quantification of adverse reactions to newly marketed drugs.6-9 Though these proposals differed in detail, they all possessed several common features: firstly, that a cohort of patients starting treatment with a particular drug should be identified; secondly, that the cohort should be sufficiently large to allow rarer adverse reactions to be detected; and, thirdly, that the system should look at adverse events (and not merely suspected adverse reactions) suffered by patients from the time of starting treatment to the end of the inquiry.
Several large scale postmarketing studies have now been undertaken specifically to detect adverse drug reactions, and three are of particular interest because of the contrasting methods used. They include a study of cimetidine The need for controls in postmarketing surveillance studies seems to me to be clear. This is particularly the case when adverse "events" are to be recorded, when the underlying disorder is itself associated with substantial morbidity or mortality (for example, hypertension), or when it is likely that the drug will increase the incidence ofcommonly occurring symptoms or diseases (for example, impotence or diabetes mellitus). Thus, in the recent ketotifen study, the significance of adverse "events" occurring during follow up (including weight gain and non-fatal myocardial infarction) is impossible to evaluate. Yet the choice of a control population is difficult. The ideal group-patients suffering from the same disease but undergoing no active treatment-is unattainable for long term studies except in very special circumstances. More realistic controls include patients treated with a comparable drug (as in the benoxaprofen study) or a sample of the general population (as in the cimetidine study).
For the future we need to be able to identify the drugs to which these postmarketing surveillance techniques might most profitably be applied. In general, the balance between risk and benefit most needs to be examined with drugs for disorders which are not life threatening and when reasonably safe alternatives are already available. Such studies are likely to be worth while, however, only if they enrol at least 10 times the number of patients in the premarketing trials and include a reasonable comparative control group. They will therefore need to include at least 10 000 patients and 10 000 controls, and the cost will be substantial. Yet they will detect, with 95% confidence, only those events occurring in one in 3000 patients. For many drugs, and for the recognition and confirmation of less common reactions, we must therefore continue to rely on published anecdotal reports, the yellow card system, case-control studies, and examination ofmortality and morbidity statistics. 
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